Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
Ulagamadesan VenkatesanZhuoru LiChinthanie RamasundarahettigeSeungJae BaekKelley R H BranchStephano Del PratoCarolyn Su Ping LamRenato Deláscio LopesRichard E PratleyJulio RosenstockNaveed SattarPublished in: Circulation (2023)
gov; Unique identifier: NCT03496298.